February 13, 2007 -- Sanofi-Aventis received a third delay from the FDA for weight-loss drug, Acomplia; Seattle Genetics won orphan drug designation for two cancer drug candidates; Somaxon will file for approval of its sedative Silenor in Q3 without long-term carcinogenicity tests; Beckman Coulter exercised an option to continue using technology belonging to Critical Therapeutics; Monogram and Pfizer announced that HIV drug maraviroc won priority review; Human Genome Sciences and GlaxoSmithKline began Phase 3 clinical trials of their lupus drug; and MGI Pharma received a five-year extension of their patent for anti-nausea drug Aloxi. The Centient Biotech 200™ rose 8 points to 4039, an increase of .21%. More details...
